Research Analysts Issue Forecasts for BMY Q2 Earnings

Bristol-Myers Squibb (NYSE:BMY) – Equities researchers at William Blair decreased their Q2 2025 earnings per share (EPS) estimates for Bristol-Myers Squibb in a report released on Tuesday, April 15th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will earn $1.57 per share for the quarter, down from their previous estimate of $1.61. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $6.74 per share. William Blair also issued estimates for Bristol-Myers Squibb’s Q1 2026 earnings at $1.56 EPS, Q2 2026 earnings at $1.56 EPS, Q3 2026 earnings at $1.63 EPS, Q4 2026 earnings at $1.59 EPS and FY2026 earnings at $6.35 EPS.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%.

Several other equities research analysts have also commented on BMY. UBS Group decreased their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research report on Friday, April 11th. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Citigroup raised their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Truist Financial upped their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald lifted their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $57.67.

Bristol-Myers Squibb Price Performance

Shares of BMY opened at $49.33 on Thursday. The stock’s 50 day moving average is $57.24 and its two-hundred day moving average is $56.68. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The firm has a market capitalization of $100.37 billion, a PE ratio of -11.16, a P/E/G ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33.

Institutional Trading of Bristol-Myers Squibb

A number of institutional investors and hedge funds have recently modified their holdings of the business. Morse Asset Management Inc boosted its holdings in shares of Bristol-Myers Squibb by 25.0% during the third quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company’s stock valued at $517,000 after acquiring an additional 2,000 shares during the period. Tudor Financial Inc. acquired a new stake in shares of Bristol-Myers Squibb in the third quarter valued at approximately $250,000. Pine Valley Investments Ltd Liability Co raised its holdings in shares of Bristol-Myers Squibb by 1.3% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company’s stock valued at $2,323,000 after buying an additional 575 shares during the last quarter. World Investment Advisors LLC boosted its position in shares of Bristol-Myers Squibb by 18.7% during the third quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company’s stock worth $2,282,000 after buying an additional 6,954 shares during the period. Finally, Arvest Bank Trust Division bought a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $1,724,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Samit Hirawat acquired 1,823 shares of the business’s stock in a transaction on Friday, February 14th. The shares were purchased at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.07% of the stock is owned by company insiders.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.03%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.